CasZyme
CasZyme is a Vilnius-based CRISPR biotech developing ultra-compact Cas12l nucleases and custom gene editing services for pharmaceutical, agricultural, and diagnostics clients, monetizing through licensing deals and bespoke R&D partnerships.
- Company typePrivate
- Founded2017
- HeadquartersVilnius, Lithuania
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CasZyme does
CasZyme is a Vilnius, Lithuania-based biotechnology company founded in 2017 that develops CRISPR-Cas molecular tools, with a core focus on ultra-compact Cas12l nucleases optimized for therapeutic delivery via adeno-associated viruses (AAVs). The company's technology platform spans bioinformatics and AI-driven discovery of novel nucleases from metagenomic databases, rational design and directed evolution of protein variants, comprehensive biochemical characterization, and mRNA synthesis and optimization services. CasZyme serves five application areas: therapeutics, agri-tech, diagnostics, research tools, and industrial biotech, providing both custom CRISPR solution development and licensing of proprietary technologies such as Cas12l to enterprise partners including Corteva Agriscience and BetterSeeds.
The company monetizes primarily through professional services (custom CRISPR solution development, nuclease characterization, protein evolution, mRNA services) and licensing/royalty arrangements with pharmaceutical, agricultural, and biotech clients. Its go-to-market is B2B and partner-centric, with no traditional distribution channels — relationships are driven by direct enterprise sales and strategic licensing deals, supplemented by participation in industry conferences (e.g., ASGCT) and EU-funded collaborative R&D consortia (Eurostars/EUREKA projects including UNCOVER, CREATIVE, SMART, and WiFIX). The firm is privately held as an LLC, employs 11-50 people, and has sustained operations through a combination of grant funding, service revenue, and licensing income rather than disclosed venture capital rounds.
Recent strategic activity includes the 2026 collaboration with BetterSeeds and Corteva Agriscience to combine Cas12l nucleases with viral delivery platforms for crop gene editing, the EUR 1M WiFIX Eurostars grant for nucleic acid therapeutic delivery, publication of peer-reviewed Cas12l validation, and ongoing expansion into diagnostics via the UNCOVER platform. The competitive position rests on proprietary ultra-compact nuclease IP, founder provenance as CRISPR-Cas9 pioneers, and an integrated discovery-to-characterization service stack, though revenue concentration on a small number of named enterprise partners and absence of disclosed funding rounds indicate an early-stage commercial profile.
CasZyme firmographics
Firmographics- Name
- CasZyme
- Legal name
- Caszyme, LLC
- Website
- https://caszyme.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CasZyme is a Vilnius-based CRISPR biotech developing ultra-compact Cas12l nucleases and custom gene editing services for pharmaceutical, agricultural, and diagnostics clients, monetizing through licensing deals and bespoke R&D partnerships.
- Ownership category
- akta.pro rank
CasZyme industry classification
Industry- Product category
- CRISPR Gene Editing Tools and Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
Keywords
Where CasZyme is headquartered
LocationHeadquarters
- HQ city
- Vilnius
- HQ country
- Lithuania
- HQ region
- Europe
Offices1 record
Markets served
CasZyme business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Custom CRISPR Solutions Development: CasZyme provides custom CRISPR solutions to partners, developing tailored gene editing tools and services. The company combines deep experience and a dynamic platform to deliver world-class CRISPR solutions to partners across healthcare and sustainability sectors.
- Licensing of Proprietary Technologies: CasZyme licenses its Cas12l nucleases and related technologies to partners such as Corteva Agriscience, enabling viral delivery of gene edits directly into crops.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
CasZyme product offering
Product offeringCore offering
CasZyme develops and provides custom CRISPR-Cas molecular tools and solution development services, centered on its proprietary ultra-compact Cas12l nuclease platform optimized for therapeutic delivery via adeno-associated viruses and for viral vector delivery in crops. The company combines deep bioinformatics/AI-driven discovery, protein engineering (rational design and directed evolution), biochemical characterization, and mRNA synthesis/optimization to deliver tailored gene editing solutions to partners in therapeutics, agriculture, diagnostics, research tools, and industrial biotechnology. Revenue is generated through professional service engagements and licensing of proprietary Cas12l technology.
Product overview
CasZyme operates as a CRISPR technology platform company offering specialized services and proprietary nucleases. The core product is the Cas12l Platform featuring ultra-compact Cas12l nucleases optimized for therapeutic delivery. The service portfolio includes Custom CRISPR Solutions (end-to-end development from bioinformatics through verification), Nuclease Expertise (screening, purification, biochemical analysis), mRNA Synthesis and Optimization, and Protein Evolution. These offerings support five application areas: Therapeutics, Agri-Tech, Diagnostics, Research Tools, and Industrial Biotech. The company leverages over 15 years of CRISPR expertise to deliver market-ready products through a flexible, diverse platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Cas12l Platform
Quantifiable outcome
- 50%+ reduction in time and cost compared to traditional tissue culture approaches
Companies that use CasZyme
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles4 records
CasZyme technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
CasZyme partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- BetterSeedscoreCasZyme and BetterSeeds announced a collaboration to overcome the tissue culture bottleneck in plant gene editing by combining CasZyme's ultra-compact Cas12l nucleases with BetterSeeds' viral vector-based EDGE delivery platform. The partnership aims to eliminate or substantially reduce reliance on tissue culture, which is time-consuming, costly, and genotype-dependent, potentially cutting time and cost by more than 50% compared to traditional approaches.
- Corteva AgrisciencecoreCorteva Agriscience has licensed Cas12l to both CasZyme and BetterSeeds, enabling viral delivery of gene edits directly into crops. This licensing arrangement makes CRISPR technology more accessible to a broader range of seed companies.
- Vilnius University ConsortiumcorePart of the EUREKA-Eurostars 3 project UNCOVER (Universal CRISPR-based Detection Platform for Versatile and Rapid Diagnostics) along with nSAGE and other partners. CasZyme is a member of the Vilnius University Consortium in the 'Implementation of Mission-Driven Science and Innovation Programmes' project focused on Innovations for Health.
- VU (Vilnius University)minorListed as a partner on CasZyme's website with logo displayed among other partner organizations. Vilnius University is also part of the consortium in EU grants.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
CasZyme competitors and assessment
Company assessmentDirect peers
- Metagenomi: Metagenomi uses AI and metagenomic databases to discover novel CRISPR nuclease systems for therapeutic gene editing — the same core discovery thesis and methodology as CasZyme, but focused on human therapeutics development.
- ToolGen: ToolGen is a Korea-based CRISPR tools company that discovers and licenses novel Cas nucleases for therapeutic and agricultural gene editing, overlapping with CasZyme's nuclease platform and licensing model.
- Caribou Biosciences: Caribou Biosciences is a CRISPR platform company developing Cas nuclease-derived tools for both therapeutic and non-therapeutic applications, sharing CasZyme's platform-tools orientation and multi-vertical licensing approach.
Broad incumbents
- Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing CRISPR-based therapeutics using its own proprietary nucleases; it represents a well-funded incumbent competing for the same therapeutic licensing and partnership opportunities CasZyme targets.
- Editas Medicine: Editas Medicine is a clinical-stage gene editing company with proprietary Cas9 and Cas12a programs across therapeutic areas, operating as a broad incumbent in the same CRISPR therapeutics space as CasZyme.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage gene editing company with approved Cas9-based therapy (Casgevy), representing a well-capitalized incumbent in the therapeutic CRISPR market where CasZyme's nuclease IP could be licensed.
- Beam Therapeutics: Beam Therapeutics develops base editing and prime editing therapeutics using proprietary enzymes, an adjacent gene editing modality that competes for the same therapeutic partnerships and licensing economics CasZyme targets.
- New England Biolabs: NEB is a leading life science reagents and enzyme company that distributes research-use CRISPR tools, listed as a CasZyme partner. It represents a broad incumbent in the same research tools and nuclease distribution market.
- Thermo Fisher Scientific: Thermo Fisher is a global life science tools and reagents giant with extensive gene editing and CRISPR product lines, listed as a CasZyme partner. It serves as a broad incumbent across the same customer base.
Emerging players
- Inscripta (now part of Element Biosciences): Inscripta developed a CRISPR platform for gene editing and was acquired by Element Biosciences; it represents an emerging peer in CRISPR tools commercialization, with comparable nucleic acid manipulation focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CasZyme social profiles
Digital presenceCasZyme financial estimates
Financial estimateRevenue estimate
Valuation estimate
CasZyme leadership team
Management profileNumber of profiles
CasZyme funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CasZyme M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CasZyme
What does CasZyme do?
CasZyme develops and provides custom CRISPR-Cas molecular tools and solution development services, centered on its proprietary ultra-compact Cas12l nuclease platform optimized for therapeutic delivery via adeno-associated viruses and for viral vector delivery in crops. The company combines deep bioinformatics/AI-driven discovery, protein engineering (rational design and directed evolution), biochemical characterization, and mRNA synthesis/optimization to deliver tailored gene editing solutions to partners in therapeutics, agriculture, diagnostics, research tools, and industrial biotechnology. Revenue is generated through professional service engagements and licensing of proprietary Cas12l technology.
Is CasZyme a public or private company?
CasZyme is a private company. It is classified as unknown and is currently operating.
When was CasZyme founded?
CasZyme was founded in 2017. It employs 11 to 50 people.
Where is CasZyme based?
CasZyme is headquartered in Vilnius, Lithuania, in the Europe region.
How does CasZyme make money?
Two revenue lines are on record. Custom CRISPR Solutions Development is the primary driver. The others are licensing of Proprietary Technologies.
Who are CasZyme's main competitors?
Direct peers on record are Metagenomi, ToolGen and Caribou Biosciences. Broad incumbents are Intellia Therapeutics, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, New England Biolabs and Thermo Fisher Scientific. Inscripta (now part of Element Biosciences) is listed as an emerging player.
Does CasZyme have an API?
No public API is recorded for CasZyme.
What industry is CasZyme in?
CasZyme's product category is CRISPR Gene Editing Tools and Services. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.